The DNA-based Cologuard stool test may benefit Alaska Natives, who have limited access to colonoscopy, low screening rates and a high prevalence of colorectal cancer, a Mayo Clinic study said. The study of 661 Alaska Native adults found the DNA test detected more relevant colorectal neoplasia than fecal immunochemical testing alone.
Spleen stiffness can predict and distinguish large and small esophageal varices in patients with cirrhosis, researchers reported in The American Journal of Gastroenterology. The study, which used transient elastography to measure spleen and liver stiffness, included data from 174 patients. Researchers said the noninvasive diagnostic procedure was helpful in determining patients who were at risk for bleeding and can help identify which patients need endoscopy.
Researchers at the University of Maryland and Johns Hopkins University have created photonovels in Chinese, Korean and Vietnamese to help raise hepatitis B awareness among Asian-American communities. Although Asian-Americans make up about 5% of the U.S. population, about half the 1 million Americans who have chronic hepatitis B are of Asian/Pacific Islander heritage.
Stool DNA tests may be a good addition to colonoscopy surveillance for colorectal neoplasia in patients with inflammatory bowel disease, Mayo Clinic researchers said. Co-author Dr. John Kiesel said the goal is to better stratify the risk of IBD patients so that those at high risk of colorectal cancer might get more frequent colonoscopies while those at low risk may have exams less often.
A report in the International Journal of Cancer found that high blood levels of vitamin D may reduce the risk of colorectal cancer. A team led by the International Prevention Research Institute in France analyzed data from nine studies and found that for every 10-nanograms-per-milliliter increase in levels of vitamin D, the risk of colorectal cancer decreased by 15%.